Parameswaran Hari

Company: Obsidian Therapeutics

Job title: Chief Development Officer

Seminars:

Next Generation TIL: OBX-115 Engineered TIL Cell Therapy with Regulatable mbIL15 9:30 am

• OBX-115 is an engineered TIL cell therapy that leverages regulatable membrane-bound IL15 (mbIL15) to improve the expansion, persistence, safety, and efficacy of TIL cell therapy for patients with solid tumors • Unlike IL2, mbIL15 promotes a predominant CD8+, memory, and “stem-like” progenitor phenotype, and does not increase immunosuppressive regulatory T-cells • Clinically, we have…Read more

day: Day 1